Novo Nordisk shifts its recruitment focus to China, expanding operations to meet rising demand for Ozempic and Wegovy in the ...

In an indication of the challenges of meeting demand for Novo Nordisk’s weight-loss blockbuster, the company said Monday it would spend $11 billion to buy three manufacturing facilities to ramp ...

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

Novo Nordisk landed in hot water with the FDA following an inspection at one of the drugmaker’s key semaglutide and insulin manufacturing plants this past spring. The regulatory reprimand ...

The new plant will be one of the largest manufacturing investments in Novo Nordisk’s history and will add 1.4 million sq ft of production space for aseptic manufacturing and finished production ...

The Novo Nordisk Foundation is funding the creation of a cell therapy development and manufacturing facility in Denmark with one of the largest investments in the sector in Europe. The Foundation ...

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...

These Catalent sites are already involved in Novo Nordisk manufacturing contracts, which are largely tied to ramping up supply of the firm’s obesity drug Wegovy. Novo Nordisk expects that ...

Novo Nordisk has become Europe’s most valuable company due to soaring demand for its weight-loss-aiding drugs Wegovy, Semaglutide, and Ozempic. But as the effective backbone of the Danish ...